These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15638959)

  • 1. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
    Herbst RS; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S7-S19. PubMed ID: 15638959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
    Fuster LM; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting epidermal growth factor receptor in lung cancer.
    Baselga J; Albanell J
    Curr Oncol Rep; 2002 Jul; 4(4):317-24. PubMed ID: 12044241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S20-3. PubMed ID: 15638953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer.
    Cascone T; Morelli MP; Ciardiello F
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii46-48. PubMed ID: 16608981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
    Chen YM
    J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
    Sakurada A; Shepherd FA; Tsao MS
    Clin Lung Cancer; 2006 May; 7 Suppl 4():S138-44. PubMed ID: 16764754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of EGFR inhibitors in nonsmall cell lung cancer.
    Ciardiello F; De Vita F; Orditura M; Tortora G
    Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.